DMD and Duchenne muscular dystrophy: In our analysis, viltolarsen (indication for Duchenne muscular dystrophy with deletion of the dystrophin-encoding gene that can be treated by exon 53 skipping, approved on March 25, 2002) is the only product for which this system was applied.